Todd Chace, DO
Family Medicine · Englewood, FLNPI 1750428660
Payments from drug & device makers
Across 248 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$707
- Amgen$522
- Bayer$338
- Esperion Therapeutics, Inc.$254
- AstraZeneca$251
- AbbVie$246
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,201100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $707 |
| Amgen(2 entities) | 34 | $522 |
| Bayer | 15 | $338 |
| Esperion Therapeutics, Inc. | 14 | $254 |
| AstraZeneca | 14 | $251 |
| AbbVie | 13 | $246 |
| Lilly USA, LLC | 10 | $196 |
| Pfizer | 11 | $160 |
| Boston Scientific | 5 | $153 |
| Merck | 12 | $135 |
| Exact Sciences | 6 | $133 |
| Johnson & Johnson | 6 | $102 |
| Novartis | 7 | $99 |
| Amarin Pharma, Inc. | 5 | $90 |
| Corcept Therapeutics | 5 | $85 |
| Kowa Pharmaceuticals America, Inc. | 5 | $75 |
| Astellas Pharma US Inc | 4 | $72 |
| Radius Health, Inc. | 4 | $60 |
| GSK | 4 | $52 |
| GRT US Holding, Inc. | 2 | $45 |
| Almatica Pharma LLC | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Antares Pharma, Inc. | 2 | $31 |
| Eisai Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Abiomed | 1 | $23 |
| Optinose US, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| GE HealthCare | 1 | $16 |
| Edwards Lifesciences | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Nevro Corp. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $8 |
How this compares
$4,201 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 192 | $238,875 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $58,656 |
| FarxigaDapagliflozin Propanediol | 63 | $54,992 |
| OzempicSemaglutide | 33 | $44,823 |
| CreonLipase/Protease/Amylase | 12 | $43,081 |
| XareltoRivaroxaban | 33 | $41,585 |
| JardianceEmpagliflozin | 16 | $29,739 |
| JanuviaSitagliptin Phosphate | 19 | $21,218 |
| EntrestoSacubitril/Valsartan | 18 | $14,173 |
| Repatha SureclickEvolocumab | 17 | $13,087 |
| LinzessLinaclotide | 18 | $12,840 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $11,798 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,172 |
| KerendiaFinerenone | 14 | $8,720 |
| Atorvastatin Calcium | 830 | $7,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $160 | $238,875192 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $52 | $68,82956 claims |
| AstraZenecaFarxiga, Symbicort | $251 | $66,79090 claims |
| AbbVieCreon, Linzess, Synthroid | $246 | $59,51691 claims |
| Novo NordiskOzempic | $707 | $44,82333 claims |
| Johnson & JohnsonXarelto | $102 | $41,58533 claims |
| Boehringer IngelheimJardiance | $34 | $29,73916 claims |
| MerckJanuvia | $135 | $21,21819 claims |
| NovartisEntresto | $99 | $14,17318 claims |
| BayerKerendia | $338 | $8,72014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Englewood
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.